{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:29:25Z","timestamp":1790771365344,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.07.020","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T17:42:07Z","timestamp":1630172527000},"page":"208-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Therapeutics development for Ebola virus disease: A recent scenario"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-239X","authenticated-orcid":false,"given":"Chiranjib","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.07.020_sref1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"Malvy","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.07.020_bib2","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-med-052915-015604","article-title":"Ebola: anatomy of an epidemic","volume":"68","author":"Lo","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coph.2021.07.020_bib3","doi-asserted-by":"crossref","first-page":"20160308","DOI":"10.1098\/rstb.2016.0308","article-title":"Heterogeneities in the case fatality ratio in the West African Ebola outbreak 2013\u20132016","volume":"372","author":"Garske","year":"2017","journal-title":"Phil Trans Biol Sci"},{"key":"10.1016\/j.coph.2021.07.020_bib4","article-title":"Ebola virus disease (Primer)","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev: Disease Prim"},{"key":"10.1016\/j.coph.2021.07.020_sref5","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.020_bib6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nri1154","article-title":"Ebola virus: from discovery to vaccine","volume":"3","author":"Feldmann","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2021.07.020_bib7","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1086\/514299","article-title":"Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection","volume":"179","author":"Leirs","year":"1999","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.coph.2021.07.020_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4103\/1995-7645.267581","article-title":"Ebola virus disease: recent advances in diagnostics and therapeutics","volume":"12","author":"Jagga","year":"2019","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.coph.2021.07.020_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1189\/jlb.4RI0316-099RR","article-title":"Molecular mechanisms of Ebola pathogenesis","volume":"100","author":"Rivera","year":"2016","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.coph.2021.07.020_sref10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrd.2017.251","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","volume":"17","author":"Cross","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2021.07.020_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.puhe.2021.03.027","article-title":"Impact of recurrent outbreaks of Ebola virus disease in Africa: a meta-analysis of case fatality rates","volume":"195","author":"Kawuki","year":"2021","journal-title":"Publ Health"},{"key":"10.1016\/j.coph.2021.07.020_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251101","article-title":"The impact of malaria coinfection on Ebola virus disease outcomes: a systematic review and meta-analysis","volume":"16","author":"Edwards","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.07.020_bib13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.celrep.2019.03.020","article-title":"Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans","volume":"27","author":"Rijal","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2021.07.020_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/vaccines9050457","article-title":"Engineered human monoclonal scFv to receptor binding domain of ebolavirus","volume":"9","author":"Densumite","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.coph.2021.07.020_sref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-016-0105-1","article-title":"Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus","volume":"5","author":"Karthick","year":"2016","journal-title":"Infect Diseases Povert"},{"key":"10.1016\/j.coph.2021.07.020_bib16","article-title":"Ebola eradication may need wider partnership","volume":"186","author":"Agoramoorthy","year":"2014","journal-title":"CMAJ (Can Med Assoc J)"},{"key":"10.1016\/j.coph.2021.07.020_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.coph.2021.07.020_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.coph.2021.07.020_bib19","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2021.07.020_bib20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)\u2014Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2021.07.020_bib21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.arcmed.2020.05.001","article-title":"Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more","volume":"51","author":"Saha","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.coph.2021.07.020_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.arcmed.2020.09.005","article-title":"Response to: status of remdesivir: not yet beyond question!","volume":"52","author":"Saha","year":"2021","journal-title":"Arch Med Res"},{"key":"10.1016\/j.coph.2021.07.020_bib23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/acs.biochem.1c00292","article-title":"Mechanism of inhibition of the reproduction of SARS-CoV-2 and Ebola viruses by remdesivir","volume":"60","author":"Wang","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.coph.2021.07.020_sref24","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A\u00a0randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.020_bib25","doi-asserted-by":"crossref","first-page":"104951","DOI":"10.1016\/j.meegid.2021.104951","article-title":"Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2","author":"Shawan","year":"2021","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.coph.2021.07.020_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2021.07.020_sref27","first-page":"2365","article-title":"Monoclonal antibody therapy for Ebola virus disease","volume":"vol. 381","author":"Levine","year":"2019"},{"key":"10.1016\/j.coph.2021.07.020_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/BTT.S259069","article-title":"Immunotherapeutics for Ebola virus disease: hope on the horizon","volume":"15","author":"O'Donnell","year":"2021","journal-title":"Biol Targets & Ther"},{"key":"10.1016\/j.coph.2021.07.020_bib29","first-page":"22","article-title":"Monoclonal antibody approved to treat Ebola","volume":"121","author":"Aschenbrenner","year":"2021","journal-title":"Am J Nurs"},{"key":"10.1016\/j.coph.2021.07.020_bib30","first-page":"1","article-title":"REGN-EB3: first approval","volume":"11","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2021.07.020_bib31","first-page":"240","article-title":"Drug combination therapy for emerging viral diseases","volume":"S1359\u20136446","author":"Shyr","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.coph.2021.07.020_bib32","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A\u00a0randomized, controlled trial of ZMapp for Ebola virus infection","volume":"375","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.020_bib33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.07.020_bib34","first-page":"1","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Disease Prim"},{"key":"10.1016\/j.coph.2021.07.020_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"Van Griensven","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.020_sref36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S1473-3099(18)30397-9","article-title":"Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study","volume":"18","author":"Sivapalasingam","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:14Z","timestamp":1761461834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221001193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"alternative-id":["S1471489221001193"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.020","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutics development for Ebola virus disease: A recent scenario","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}